| Literature DB >> 26444777 |
Nathalie Pierrot1,2, Renaud Lhommel1,2,3, Lisa Quenon1,2, Bernard Hanseeuw1,4, Laurence Dricot1,2, Christian Sindic1,2, Jean-Marie Maloteaux1,2,4, Jean-Noël Octavea1,2, Adrian Ivanoiu1,2,4.
Abstract
We present the effects of Targretin® (bexarotene) on cognition and biomarkers in a patient with mild Alzheimer's disease (AD). Targretin® is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux. After 6 months of treatment with Targretin® 300 mg/day, memory improved by about 40% and the tau protein in the cerebrospinal fluid decreased by about 20% . No significant side effects were noticed. This observation in a single patient indicates that Targretin® may improve memory performance and biological markers at an early stage of AD.Entities:
Keywords: Amyloid-β and tau markers; Targretin/bexarotene; cholesterol; cognition
Mesh：
Substances：
Year: 2016 PMID： 26444777 DOI： 10.3233/JAD-150405
Source DB: PubMed Journal: J Alzheimers Dis ISSN： 1387-2877 Impact factor: 4.472